Market Research Logo

Arterial Thrombosis - Pipeline Review, H2 2015

Arterial Thrombosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Arterial Thrombosis - Pipeline Review, H2 2015’, provides an overview of the Arterial Thrombosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arterial Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arterial Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arterial Thrombosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arterial Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Arterial Thrombosis Overview
Therapeutics Development
Pipeline Products for Arterial Thrombosis - Overview
Pipeline Products for Arterial Thrombosis - Comparative Analysis
Arterial Thrombosis - Therapeutics under Development by Companies
Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes
Arterial Thrombosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Arterial Thrombosis - Products under Development by Companies
Arterial Thrombosis - Products under Investigation by Universities/Institutes
Arterial Thrombosis - Companies Involved in Therapeutics Development
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Johnson & Johnson
Sanofi
Arterial Thrombosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AS-1468240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-1645 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-6537 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-593214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-5539 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ER-410660 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-375 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PZ-128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-216471 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temanogrel hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arterial Thrombosis - Recent Pipeline Updates
Arterial Thrombosis - Dormant Projects
Arterial Thrombosis - Product Development Milestones
Featured News & Press Releases
Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Arterial Thrombosis, H2 2015
Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Arterial Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015
Arterial Thrombosis - Pipeline by AstraZeneca Plc, H2 2015
Arterial Thrombosis - Pipeline by Bayer AG, H2 2015
Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015
Arterial Thrombosis - Pipeline by Johnson & Johnson, H2 2015
Arterial Thrombosis - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Arterial Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015
Arterial Thrombosis - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Arterial Thrombosis, H2 2015
Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report